PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity
- Conditions
- Interventions
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 902
- Registration Number
- NCT05579977
- Locations
- π¨π¦
LMC Clinical Research Inc. (Bayview), Toronto, Ontario, Canada
πΊπΈSan Fernando Valley Health Institute, Canoga Park, California, United States
πΊπΈCatalina Research Institute, LLC, Montclair, California, United States
To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting.
- Conditions
- Interventions
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05576051
- Locations
- πΊπΈ
Pfizer, New York, New York, United States
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 47
- Registration Number
- NCT05573555
- Locations
- πΊπΈ
Moffitt McKinley Hospital, Tampa, Florida, United States
πΊπΈStanford Women's Cancer Center, Palo Alto, California, United States
πΊπΈUCSF Medical Center at Mission Bay, San Francisco, California, United States
Study to Evaluate Safety and Effects of Tofacitinib and Biologic Disease Modifying Antirheumatic Drugs in People Treated for Rheumatoid Arthritis
- Conditions
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05572567
- Locations
- π―π΅
Pfizer, Tokyo, Japan
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- Conditions
- Interventions
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 263
- Registration Number
- NCT05568719
- Locations
- πΊπΈ
UC Davis Health, Sacramento, California, United States
πΊπΈUC Davis Ambulatory Care Clinic, Sacramento, California, United States
πΊπΈUC Davis Hemophilia Treatment Center, Sacramento, California, United States
A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 7
- Registration Number
- NCT05567887
- Locations
- π―π΅
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Aichi, Japan
π―π΅Yamagata University Hospital, Yamagata, Japan
π―π΅Japanese Foundation for Cancer Research, Koto, Tokyo, Japan
A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir
- Conditions
- Interventions
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 436
- Registration Number
- NCT05567952
- Locations
- πΊπΈ
University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
πΊπΈMercury Street Medical Group, PLLC, Butte, Montana, United States
πΊπΈGlobal Health Clinical Trials, Miami, Florida, United States
A Study of Avelumab in Real-World Treatment for Patients With Advanced or Metastatic Urothelial Cancer
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 19
- Registration Number
- NCT05568407
- Locations
- π§π·
Hospital Moinhos de Vento, Porto Alegre, RIO Grande DO SUL, Brazil
π§π·Hospital MΓ£e de Deus/Aesc, Porto Alegre, RIO Grande DO SUL, Brazil
π§π·Hospital AlemΓ£o Oswaldo Cruz, Sao Paulo, SP, Brazil
A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 508
- Registration Number
- NCT05565391
- Locations
- πΊπΈ
Pfizer, New York, New York, United States
Resolution of Sickle Cell Leg Ulcers With Voxelotor
- Conditions
- Interventions
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 88
- Registration Number
- NCT05561140
- Locations
- π°πͺ
KEMRI-Centre for Respiratory Diseases Research-Nairobi, Nairobi, Kenya
π°πͺStrathmore University Medical Centre, Nairobi, Kenya
π°πͺKEMRI-CRDR, KEMRI Clinical Research Annex, Siaya, Kenya